Journal Article

Surgery and protontherapy in Grade I and II skull base chondrosarcoma: A comparative retrospective study

Simon, François, Bresson, Damien, El Zein, Sophie, Verillaud, Benjamin, Feuvret, Loïc, Froelich, Sébastien, Guichard, Jean-Pierre, Calugaru, Valentin, Herman, Philippe, Bernat, Anne-Laure, Labidi, Moujahed

2018

Overview

Skull base chondrosarcoma is a rare tumour usually treated by surgery and proton therapy. However, as mortality rate is very low and treatment complications are frequent, a less aggressive therapeutic strategy could be considered. The objective of this study was to compare the results of surgery only vs surgery and adjuvant proton therapy, in terms of survival and treatment adverse effects, based on a retrospective series. Monocentric retrospective study at a tertiary care centre. All patients treated for a skull base grade I and II chondrosarcoma were included. We collected data concerning surgical and proton therapy treatment and up-to-date follow-up, including Common Terminology Criteria for Adverse Events (CTCAE) scores. 47 patients (23M/24F) were operated on between 2002 and 2015; mean age at diagnosis was 47 years-old (10-85). Petroclival and anterior skull base locations were found in 34 and 13 patients, respectively. Gross total resection was achieved in 17 cases (36%) and partial in 30 (64%). Adjuvant proton therapy (mean total dose 70 GyRBE,1.8 GyRBE/day) was administered in 23 cases. Overall mean follow-up was 91 months (7-182). Of the patients treated by surgery only, 8 (34%) experienced residual tumour progression (mean delay 51 months) and 5 received second-line proton therapy. Adjuvant proton therapy was associated with a significantly lower rate of relapse (11%; p = 0.01). There was no significant difference in 10-year disease specific survival between patients initially treated with or without adjuvant proton therapy (100% vs 89.8%, p = 0.14). Difference in high-grade toxicity was not statistically significant between patients in both groups (25% (7) vs 11% (5), p = 0.10). The most frequent adverse effect of proton therapy was sensorineural hearing loss (39%). Long-term disease specific survival was not significantly lower in patients without adjuvant proton therapy, but they experienced less adverse effects. We believe a surgery only strategy could be discussed, delaying as much as possible proton therapy in cases of relapse. Further prospective studies are needed to validate this more conservative strategy in skull base chondrosarcoma.

• Publisher: Public Library of Science,Public Library of Science (PLoS)
• Subject: Adolescent / Adult / Aged / Aged, 80 and over / Analysis / Biology and Life Sciences / Child / Chondrosarcoma / Chondrosarcoma - mortality / Chondrosarcoma - pathology / Chondrosarcoma - radiotherapy / Chondrosarcoma - surgery / Complications / Disease Progression / Endoscopy / Female / Follow-Up Studies / Hearing loss / Humans / Larynx / Male / Medical prognosis / Medicine and Health Sciences / Middle Aged / Neoplasm Grading / Neoplasm, Residual / Neurosurgery / Oncology / Otolaryngology / Patients / Physical Sciences / Proton beam radiotherapy / Proton Therapy - adverse effects / Protons / Radiation therapy / Radiotherapy, Adjuvant - adverse effects / Research and Analysis Methods / Retrospective Studies / Side effects / Skull / Skull Base Neoplasms - mortality / Skull Base Neoplasms - pathology / Skull Base Neoplasms - radiotherapy / Skull Base Neoplasms - surgery / Statistical analysis / Strategy / Studies / Surgery / Survival / Terminology / Therapy / Toxicity / Treatment Outcome / Tumors / Young Adult